Clinical Trials
4 trialsNCT02521649 2015-08-13
Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer
Cancer Advances Inc.
Phase 2 Completed
NCT02518529 2015-08-10
Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients
Cancer Advances Inc.
Phase 2 Completed
NCT02518373 2015-08-07
CC5
Cancer Advances Inc.
Phase 2 Completed
NCT00044031 2014-04-17
Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma
Cancer Advances Inc.
Phase 3 Completed